Expression and significance of miR-6089 in retinoblastoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040154

Enrollment

Unknown

Registered

2020-11-22

Start date

2018-01-01

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinoblastoma

Interventions

RB?:Nil

healthy control group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as retinoblastoma and hospitalized in our hospital.

Exclusion criteria

Exclusion criteria: 1. According to different research purposes and the study of the drug requirements of the population; 2. Patients participating in other clinical trials; 3. The researchers believe that other reasons are not suitable for clinical trial subjects.

Design outcomes

Primary

Measure	Time frame
miR-6089;	—

Countries

China

Contacts

Public ContactHongfeng Yuan

Army Medical Center of PLA

yhf871@sina.com+86 13038316313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026